Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Expert Rev Gastroenterol Hepatol ; 11(8): 749-758, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28612637

RESUMEN

INTRODUCTION: Patients with inflammatory bowel diseases (IBD) require life-long medications, which even if effective have the potential to cause adverse effects as additional morbidity factors. In pediatric patients, drug therapy has more serious limitations, including impaired physical and mental development. A non-drug therapeutic option is believed to be depletion of elevated and activated granulocytes and monocytes known to release inflammatory cytokines, like the CD14+CD16+ monocyte phenotype known to release tumor necrosis factor-α. Areas covered: Granulomonocyteapheresis (GMA) with an Adacolumn as a treatment option for IBD patients has been applied for the past 15 years. This article reviews the argument that GMA is a relevant and effective non-pharmacologic intervention in pediatric IBD setting. Expert commentary: GMA with an Adacolumn has shown promise in adult, pediatric, and adolescent patients with active IBD. There is evidence of post-GMA immunomodulation in terms of increased regulatory T-cell and B-cell activities. Additionally, patients who respond to GMA may attain a favorable long-term clinical course by avoiding pharmacologicals during an early phase of their active IBD. GMA has a good safety profile, especially in difficult-to-treat and pediatric settings. An additional trial is warranted to assess the efficacy of GMA in the early phase of pediatric IBD to optimize patient selection.


Asunto(s)
Colitis Ulcerosa/terapia , Enfermedad de Crohn/terapia , Granulocitos/inmunología , Leucaféresis/métodos , Monocitos/inmunología , Adolescente , Edad de Inicio , Antiinflamatorios/uso terapéutico , Niño , Preescolar , Colitis Ulcerosa/diagnóstico , Colitis Ulcerosa/inmunología , Enfermedad de Crohn/diagnóstico , Enfermedad de Crohn/inmunología , Fármacos Gastrointestinales/uso terapéutico , Humanos , Leucaféresis/instrumentación , Resultado del Tratamiento
2.
Nihon Shokakibyo Gakkai Zasshi ; 106(6): 834-9, 2009 Jun.
Artículo en Japonés | MEDLINE | ID: mdl-19498316

RESUMEN

A 66-year-old woman, given a diagnosis of alcoholic liver cirrhosis in 2004, had improved her liver function by abstinence from drinking. Since then, she has drunk 1 to 2 liters of Yakon tea per day. Her liver function deteriorated and T. Bil was 13.2mg/dl and AST was 291U/l in February 2005. Given the positive DLST for Yakon tea, Yakon tea-induced hepatitis was diagnosed. After cessation of the intake of the tea, her liver function gradually improved. Since there has been no report on Yakon induced hepatitis and it has been thought to be a safe supplement, we here report this intriguing case.


Asunto(s)
Enfermedad Hepática Crónica Inducida por Sustancias y Drogas/etiología , Cirrosis Hepática Alcohólica/complicaciones , Anciano , Suplementos Dietéticos/efectos adversos , Femenino , Humanos , Té/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA